TABLE 3.
PTS comparison of patients based on low HDL-C levels and mutation status
| Top 10th Percentile of PTS | Bottom 10th Percentile of PTS | |||||||
| Control | M+ | M− | OR (95% CI, P) | Control | M+ | M− | OR (95% CI, P) | |
| Lipid Genetics Clinic | 52/503 | 4/41 | 4/95 | M+: 0.94 (0.27–2.90, 0.583) | 51/503 | 8/41 | 24/95 | M+: 2.15 (0.86–5.19, 0.063) |
| M−: 0.38 (0.11–1.13, 0.038) | M−: 3.00 (1.67–5.35, <0.0001) | |||||||
| MHI Biobank | 119/1,198 | 3/22 | 14/179 | M+: 1.43 (0.33–5.21, 0.380) | 120/1,198 | 1/22 | 24/179 | M+: 0.43 (0.02–3.03, 0.341) |
| M−: 0.77 (0.41–1.41, 0.228) | M−: 1.39 (0.85–2.27, 0.107) | |||||||
| UPenn | 52/503 | NA | 31/349 | M+: NA | 51/503 | NA | 40/349 | M+: NA |
| M−: 0.85 (0.52–1.38, 0.280) | M−: 1.15 (0.72–1.82, 0.307) | |||||||
| Overall | 171/1,701a | 7/63 | 49/623 | M+: 1.12 (0.46–2.60, 0.455) | 171/1,701a | 9/63 | 88/623 | M+: 1.49 (0.67–3.20, 0.186) |
| M−: 0.76 (0.54–1.08, 0.063) | M−: 1.47 (1.11–1.96, <0.01) | |||||||
Whole numbers represent patient counts, with the numerator indicating the number of individuals with a PTS in the top 10th or bottom 10th percentile and the denominator indicating the total number of individuals in the patient subgroup. ORs were calculated with a confidence level of 95%. Left-tailed and right-tailed tests of significance were considered for the top 10th and bottom 10th percentiles, respectively. NA, not available. Boldface type indicates statistically significant ORs.
a
The 1KG group was counted only once, given that it was used in both the Lipid Genetics Clinic and UPenn cohorts.